Reed Levine, MD
Pain Medicine · Pasadena, CANPI 1386844868
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Vertex at 44.0% of the total. 2025 is the largest year on record at $46,538, 2.1 times the $22,177 reported in 2019. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,256 payments — averaging $79.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$44K
- Biodelivery Sciences International, Inc.$12K
- Abbott$7K
- MDD US Operations, LLC$6K
- Biogen$6K
- Medtronic$6K
- plus $18K from 40 others
What the payments were for
- Consulting fees$11,74012%
- Speaking & faculty fees$49,99850%
- Travel & lodging$13,13013%
- Food & beverage$24,35125%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOURNAVX$41,808
- BELBUCA$11,951
- SPINRAZA$6,133
- Lucemyra/Lofexidine$6,072
- Symproic$2,805
- INTELLIS ADAPTIVESTIM$2,696
- HA MINUTEMAN G3-R$2,108
- MOVANTIK$1,560
- LUCEMYRA$1,500
- SUPERION$738
- Proclaim Family of SCS IPGs$727
- SPRINT PNS System$702
- LIBERTY SI$353
- VERIFLEX$176
- VANTA ADAPTIVESTIM$148
- SYNCHROMEDII$143
- ReActiv8$134
- NURTEC ODT$125
- PROCLAIM$124
How this compares
$99,355 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 50 | $39,096 |
| OxycontinOxycodone Hcl | 51 | $37,993 |
| MovantikNaloxegol Oxalate | 34 | $16,622 |
| NucyntaTapentadol Hcl | 18 | $16,284 |
| SymproicNaldemedine Tosylate | 32 | $14,504 |
| QuliptaAtogepant | 12 | $12,179 |
| UbrelvyUbrogepant | 12 | $11,322 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $10,490 |
| Fentanyl | 63 | $9,346 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,758 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 232 | $5,950 |
| ButransBuprenorphine | 11 | $5,645 |
| Chlorzoxazone | 25 | $4,524 |
| Gabapentin | 278 | $4,152 |
| Lidocaine | 29 | $3,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta | $946 | $55,38068 claims |
| AbbVieQulipta, Ubrelvy | $828 | $23,50024 claims |
| Redhill Biopharma Inc.Movantik | $1,717 | $16,62234 claims |
| Shionogi IncSymproic | $17 | $14,50432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in Pasadena
- Ryan MattiePasadena$154K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.